西藏药业
(600211)
| 流通市值：131.60亿 | | | 总市值：131.60亿 |
| 流通股本：3.22亿 | | | 总股本：3.22亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,176,030,498.94 | 1,554,436,303.07 | 723,548,218.03 | 2,981,538,230.43 |
| 营业收入 | 2,176,030,498.94 | 1,554,436,303.07 | 723,548,218.03 | 2,981,538,230.43 |
| 二、营业总成本 | 1,545,783,223.78 | 1,092,056,208.13 | 502,684,914.58 | 1,988,734,371.46 |
| 营业成本 | 163,679,721.51 | 108,762,662.05 | 51,375,631.14 | 172,474,862.95 |
| 税金及附加 | 24,546,236.5 | 19,898,280.35 | 6,535,638.56 | 37,716,162.15 |
| 销售费用 | 1,181,425,212.27 | 846,238,844.66 | 395,451,437.34 | 1,644,299,989.97 |
| 管理费用 | 95,167,605.4 | 62,972,702.03 | 30,299,367.1 | 129,241,359.43 |
| 研发费用 | 84,654,932.72 | 57,883,864.72 | 26,475,856.6 | 74,080,120 |
| 财务费用 | -3,690,484.61 | -3,700,145.67 | -7,453,016.17 | -69,078,123.04 |
| 其中:利息费用 | 37,004,157.85 | 22,327,219.97 | 10,149,635.36 | 12,569,466.82 |
| 其中:利息收入 | 44,738,984.71 | 27,612,999.42 | 17,792,064.62 | 80,518,694.59 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -7,146,546.18 | -5,092,343.47 | -2,141,871.87 | 1,661,657.85 |
| 加:投资收益 | 11,573,198.99 | 10,108,006.18 | 1,446,799.23 | 7,481,444.41 |
| 资产处置收益 | -7,500.68 | 1,167.97 | 1,167.97 | 108,677.06 |
| 资产减值损失(新) | -4,077,365.17 | -3,864,720.25 | -173,718.59 | -4,845,488 |
| 信用减值损失(新) | 145,950.5 | 146,764.01 | - | 436,451.69 |
| 其他收益 | 174,172,831.1 | 172,695,411.58 | 96,301,242.56 | 46,185,366.49 |
| 营业利润平衡项目 | 0.01 | -0.01 | -0.01 | 0 |
| 四、营业利润 | 804,907,843.73 | 636,374,380.95 | 316,296,922.74 | 1,043,831,968.47 |
| 加:营业外收入 | 2,074,152.66 | 1,999,269.79 | 1,086,891.96 | 329,765.49 |
| 减:营业外支出 | 5,398,859.9 | 1,428,582.91 | 746,827.18 | 3,543,864.76 |
| 五、利润总额 | 801,583,136.49 | 636,945,067.83 | 316,636,987.52 | 1,040,617,869.2 |
| 减:所得税费用 | 87,466,379.37 | 65,816,713.12 | 33,803,518.58 | 123,636,913.48 |
| 六、净利润 | 714,116,757.12 | 571,128,354.71 | 282,833,468.95 | 916,980,955.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 714,116,757.12 | 571,128,354.71 | 282,833,468.95 | 916,980,955.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 775,756,549.5 | 607,962,189.14 | 298,709,306.88 | 937,931,435.32 |
| 少数股东损益 | -61,639,792.38 | -36,833,834.43 | -15,875,837.93 | -20,950,479.6 |
| 扣除非经常损益后的净利润 | 608,682,363.22 | 439,679,798.06 | 212,068,158.06 | 871,408,061.7 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 2.41 | 1.91 | 0.93 | 2.91 |
| (二)稀释每股收益 | 2.41 | 1.91 | 0.93 | 2.91 |
| 八、其他综合收益 | -28,684,314.37 | -23,721,415.55 | -12,073,799.08 | -17,441,769.97 |
| 归属于母公司股东的其他综合收益 | -28,684,314.37 | -23,721,415.55 | -12,073,799.08 | -18,051,964.49 |
| 九、综合收益总额 | 685,432,442.75 | 547,406,939.16 | 270,759,669.87 | 899,539,185.75 |
| 归属于母公司股东的综合收益总额 | 747,072,235.13 | 584,240,773.59 | 286,635,507.8 | 919,879,470.83 |
| 归属于少数股东的综合收益总额 | -61,639,792.38 | -36,833,834.43 | -15,875,837.93 | -20,340,285.08 |
| 公告日期 | 2026-10-31 | 2026-08-14 | 2026-04-29 | 2026-03-13 |
| 审计意见(境内) | | | | 标准无保留意见 |